2020 Form 10-K Financial Statement
#000162828021003336 Filed on February 25, 2021
Income Statement
Concept | 2020 | 2019 Q4 | 2019 |
---|---|---|---|
Revenue | $339.4M | $89.35M | $347.3M |
YoY Change | -2.28% | 3.56% | 1.15% |
Cost Of Revenue | $200.6M | $44.78M | $172.5M |
YoY Change | 16.3% | 5.54% | 2.4% |
Gross Profit | $138.8M | $44.57M | $174.8M |
YoY Change | -20.62% | 1.64% | -0.04% |
Gross Profit Margin | 40.88% | 49.88% | 50.33% |
Selling, General & Admin | $110.2M | $27.69M | $103.1M |
YoY Change | 6.83% | 23.89% | 10.51% |
% of Gross Profit | 79.4% | 62.13% | 59.0% |
Research & Development | $32.79M | $4.430M | $20.02M |
YoY Change | 63.79% | -2.64% | 17.26% |
% of Gross Profit | 23.63% | 9.94% | 11.45% |
Depreciation & Amortization | $24.69M | $3.540M | $13.38M |
YoY Change | 84.53% | 4.42% | -3.95% |
% of Gross Profit | 17.79% | 7.94% | 7.65% |
Operating Expenses | $143.0M | $32.13M | $123.2M |
YoY Change | 16.09% | 19.44% | 11.55% |
Operating Profit | -$4.198M | $12.44M | $51.66M |
YoY Change | -108.13% | -26.62% | -19.89% |
Interest Expense | $9.479M | -$2.080M | $13.62M |
YoY Change | -30.39% | -58.15% | -21.76% |
% of Operating Profit | -16.73% | 26.36% | |
Other Income/Expense, Net | $2.198M | -$7.960M | -$6.221M |
YoY Change | -135.33% | -1133.77% | -352.37% |
Pretax Income | -$11.48M | $2.400M | $28.63M |
YoY Change | -140.1% | -81.16% | -42.22% |
Income Tax | $1.994M | -$8.050M | -$3.040M |
% Of Pretax Income | -335.42% | -10.62% | |
Net Earnings | -$13.47M | $10.45M | $31.67M |
YoY Change | -142.55% | -21.39% | -21.84% |
Net Earnings / Revenue | -3.97% | 11.7% | 9.12% |
Basic Earnings Per Share | -$0.25 | $0.27 | $0.81 |
Diluted Earnings Per Share | -$0.25 | $0.26 | $0.79 |
COMMON SHARES | |||
Basic Shares Outstanding | 54.13M shares | 39.25M shares | 38.99M shares |
Diluted Shares Outstanding | 54.13M shares | 40.11M shares |
Balance Sheet
Concept | 2020 | 2019 Q4 | 2019 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $79.60M | $92.90M | $92.90M |
YoY Change | -14.32% | -18.08% | -18.08% |
Cash & Equivalents | $79.60M | $92.92M | $92.90M |
Short-Term Investments | |||
Other Short-Term Assets | $14.90M | $7.283M | $7.300M |
YoY Change | 104.11% | 38.94% | 40.38% |
Inventory | $35.70M | $29.18M | $29.20M |
Prepaid Expenses | |||
Receivables | $54.00M | $43.53M | $43.50M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $184.2M | $172.9M | $172.9M |
YoY Change | 6.54% | -11.52% | -11.51% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $138.6M | $116.5M | $117.4M |
YoY Change | 18.06% | 7.98% | 8.8% |
Goodwill | $15.71M | ||
YoY Change | 0.0% | ||
Intangibles | $7.336M | ||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $112.3M | $21.63M | $92.50M |
YoY Change | 21.41% | -28.46% | -17.19% |
Total Long-Term Assets | $685.6M | $233.0M | $233.0M |
YoY Change | 194.25% | -4.67% | -4.66% |
TOTAL ASSETS | |||
Total Short-Term Assets | $184.2M | $172.9M | $172.9M |
Total Long-Term Assets | $685.6M | $233.0M | $233.0M |
Total Assets | $869.8M | $405.9M | $405.9M |
YoY Change | 114.29% | -7.71% | -7.71% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $16.30M | $18.61M | $18.60M |
YoY Change | -12.37% | 3.64% | 3.33% |
Accrued Expenses | $36.80M | $37.40M | $37.40M |
YoY Change | -1.6% | 16.51% | 16.51% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $20.70M | $10.14M | $10.10M |
YoY Change | 104.95% | 268.84% | 260.71% |
Total Short-Term Liabilities | $80.50M | $66.11M | $66.10M |
YoY Change | 21.79% | 25.32% | 25.19% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $197.7M | $183.9M | $183.9M |
YoY Change | 7.5% | -30.25% | -30.26% |
Other Long-Term Liabilities | $77.40M | $28.40M | $41.30M |
YoY Change | 87.41% | -30.39% | -21.18% |
Total Long-Term Liabilities | $275.1M | $212.3M | $225.2M |
YoY Change | 22.16% | -30.27% | -28.76% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $80.50M | $66.11M | $66.10M |
Total Long-Term Liabilities | $275.1M | $212.3M | $225.2M |
Total Liabilities | $355.6M | $291.3M | $291.3M |
YoY Change | 22.07% | -21.02% | -21.01% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$136.5M | ||
YoY Change | -18.83% | ||
Common Stock | $252.0M | ||
YoY Change | 4.9% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $514.2M | $114.6M | $114.6M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $869.8M | $405.9M | $405.9M |
YoY Change | 114.29% | -7.71% | -7.71% |
Cashflow Statement
Concept | 2020 | 2019 Q4 | 2019 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$13.47M | $10.45M | $31.67M |
YoY Change | -142.55% | -21.39% | -21.84% |
Depreciation, Depletion And Amortization | $24.69M | $3.540M | $13.38M |
YoY Change | 84.53% | 4.42% | -3.95% |
Cash From Operating Activities | $16.40M | $22.42M | $80.38M |
YoY Change | -79.6% | 29.6% | 31.36% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$12.47M | -$4.740M | -$22.06M |
YoY Change | -43.47% | -35.6% | 9.59% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $7.560M | $0.00 | $0.00 |
YoY Change | -100.0% | ||
Cash From Investing Activities | -$4.912M | -$4.740M | -$22.06M |
YoY Change | -77.73% | -35.6% | 15.31% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $683.0K | $573.0K | |
YoY Change | 19.2% | 33.88% | |
Debt Paid & Issued, Net | $15.49M | $275.4M | |
YoY Change | -94.37% | 9521.8% | |
Cash From Financing Activities | -$21.86M | -2.820M | -$78.88M |
YoY Change | -72.29% | 200.0% | 1589.82% |
NET CHANGE | |||
Cash From Operating Activities | $16.40M | 22.42M | $80.38M |
Cash From Investing Activities | -$4.912M | -4.740M | -$22.06M |
Cash From Financing Activities | -$21.86M | -2.820M | -$78.88M |
Net Change In Cash | -$10.23M | 14.86M | -$20.48M |
YoY Change | -50.08% | 65.11% | -155.19% |
FREE CASH FLOW | |||
Cash From Operating Activities | $16.40M | $22.42M | $80.38M |
Capital Expenditures | -$12.47M | -$4.740M | -$22.06M |
Free Cash Flow | $28.87M | $27.16M | $102.4M |
YoY Change | -71.82% | 10.14% | 25.97% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2020 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2020 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | |
CY2020 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2020 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001521036 | |
CY2019Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2020Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtNoncurrent | |
CY2019Q4 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtNoncurrent | |
CY2020 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-12-31 | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization | |
CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization | |
CY2020Q4 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtCurrent | |
CY2019Q4 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtCurrent | |
CY2020 | dei |
Document Type
DocumentType
|
10-K | |
CY2020 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2020 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2020 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2020 | dei |
Entity File Number
EntityFileNumber
|
001-36569 | |
CY2020 | dei |
Entity Registrant Name
EntityRegistrantName
|
LANTHEUS HOLDINGS, INC. | |
CY2020 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2020 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
35-2318913 | |
CY2020 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
331 Treble Cove Road | |
CY2020Q2 | dei |
Entity Public Float
EntityPublicFloat
|
947400000 | USD |
CY2021Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
66968382 | shares |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
79612000 | USD |
CY2020 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
North Billerica | |
CY2020 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | |
CY2020 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
01862 | |
CY2020 | dei |
City Area Code
CityAreaCode
|
978 | |
CY2020 | dei |
Local Phone Number
LocalPhoneNumber
|
671-8001 | |
CY2020 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.01 par value per share | |
CY2020 | dei |
Trading Symbol
TradingSymbol
|
LNTH | |
CY2020 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2020 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2020 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2020 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2020 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2020 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2020 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2020 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2020 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
true | |
CY2020 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
92919000 | USD |
CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
54002000 | USD |
CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
43529000 | USD |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
35744000 | USD |
CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
29180000 | USD |
CY2020Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
9625000 | USD |
CY2019Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
7283000 | USD |
CY2020Q4 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
5242000 | USD |
CY2019Q4 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
0 | USD |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
184225000 | USD |
CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
172911000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
120171000 | USD |
CY2019Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
116497000 | USD |
CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
376012000 | USD |
CY2019Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
7336000 | USD |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
58632000 | USD |
CY2019Q4 | us-gaap |
Goodwill
Goodwill
|
15714000 | USD |
CY2020Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
70147000 | USD |
CY2019Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
71834000 | USD |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
60634000 | USD |
CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
21627000 | USD |
CY2020Q4 | us-gaap |
Assets
Assets
|
869821000 | USD |
CY2019Q4 | us-gaap |
Assets
Assets
|
405919000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
20701000 | USD |
CY2019Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
10143000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
16284000 | USD |
CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
18608000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
41726000 | USD |
CY2019Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
37360000 | USD |
CY2020Q4 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
1793000 | USD |
CY2019Q4 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
0 | USD |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
80504000 | USD |
CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
66111000 | USD |
CY2020Q4 | us-gaap |
Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
|
14020000 | USD |
CY2019Q4 | us-gaap |
Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
|
12883000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
197699000 | USD |
CY2019Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
183927000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
63393000 | USD |
CY2019Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
28397000 | USD |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
355616000 | USD |
CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
291318000 | USD |
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | shares |
CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | shares |
CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
66875000 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
66875000 | shares |
CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39251000 | shares |
CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
39251000 | shares |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
669000 | USD |
CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
393000 | USD |
CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
665530000 | USD |
CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
251641000 | USD |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-149946000 | USD |
CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-136473000 | USD |
CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2048000 | USD |
CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-960000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
514205000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
114601000 | USD |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
869821000 | USD |
CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
405919000 | USD |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
339410000 | USD |
CY2019 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
347337000 | USD |
CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
343374000 | USD |
CY2020 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
200649000 | USD |
CY2019 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
172526000 | USD |
CY2018 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
168489000 | USD |
CY2020 | us-gaap |
Gross Profit
GrossProfit
|
138761000 | USD |
CY2019 | us-gaap |
Gross Profit
GrossProfit
|
174811000 | USD |
CY2018 | us-gaap |
Gross Profit
GrossProfit
|
174885000 | USD |
CY2020 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
40901000 | USD |
CY2019 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
41888000 | USD |
CY2018 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
43159000 | USD |
CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
69270000 | USD |
CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
61244000 | USD |
CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
50167000 | USD |
CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32788000 | USD |
CY2019 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20018000 | USD |
CY2018 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17071000 | USD |
CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
142959000 | USD |
CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
123150000 | USD |
CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
110397000 | USD |
CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4198000 | USD |
CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
51661000 | USD |
CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
64488000 | USD |
CY2020 | us-gaap |
Interest Expense
InterestExpense
|
9479000 | USD |
CY2019 | us-gaap |
Interest Expense
InterestExpense
|
13617000 | USD |
CY2018 | us-gaap |
Interest Expense
InterestExpense
|
17405000 | USD |
CY2020 | us-gaap |
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
|
0 | USD |
CY2019 | us-gaap |
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
|
-3196000 | USD |
CY2018 | us-gaap |
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
|
0 | USD |
CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2198000 | USD |
CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-6221000 | USD |
CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2465000 | USD |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-11479000 | USD |
CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
28627000 | USD |
CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
49548000 | USD |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1994000 | USD |
CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-3040000 | USD |
CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
9030000 | USD |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13473000 | USD |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
31667000 | USD |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
40518000 | USD |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.25 | |
CY2019 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.81 | |
CY2018 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.06 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.25 | |
CY2019 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.79 | |
CY2018 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.03 | |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54134000 | shares |
CY2019 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38988000 | shares |
CY2018 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38233000 | shares |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54134000 | shares |
CY2019 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
40113000 | shares |
CY2018 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39501000 | shares |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13473000 | USD |
CY2018 | lnth |
Forfeiture Of Dividend Equivalent Rights
ForfeitureOfDividendEquivalentRights
|
355000 | USD |
CY2018 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-74000 | USD |
CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
71002000 | USD |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
31667000 | USD |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
31667000 | USD |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
40518000 | USD |
CY2020 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
330000 | USD |
CY2019 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
148000 | USD |
CY2018 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-74000 | USD |
CY2020 | us-gaap |
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
-1418000 | USD |
CY2019 | us-gaap |
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
0 | USD |
CY2018 | us-gaap |
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
0 | USD |
CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1088000 | USD |
CY2019 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
148000 | USD |
CY2018 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-74000 | USD |
CY2020 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14561000 | USD |
CY2019 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
31815000 | USD |
CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
40444000 | USD |
CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
23291000 | USD |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
40518000 | USD |
CY2018 | lnth |
Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan
StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan
|
1580000 | USD |
CY2018 | lnth |
Vesting Of Restricted Stock Awards Value Net
VestingOfRestrictedStockAwardsValueNet
|
0 | USD |
CY2018 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
3386000 | USD |
CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8718000 | USD |
CY2019 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
148000 | USD |
CY2019 | lnth |
Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan
StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan
|
1746000 | USD |
CY2019 | lnth |
Vesting Of Restricted Stock Awards Value Net
VestingOfRestrictedStockAwardsValueNet
|
0 | USD |
CY2019 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
2454000 | USD |
CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
12492000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
114601000 | USD |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13473000 | USD |
CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1088000 | USD |
CY2020 | lnth |
Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan
StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan
|
760000 | USD |
CY2020 | lnth |
Vesting Of Restricted Stock Awards Value Net
VestingOfRestrictedStockAwardsValueNet
|
0 | USD |
CY2020 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
2129000 | USD |
CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
3776000 | USD |
CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
394334000 | USD |
CY2020 | lnth |
Adjustments To Additional Paid In Capital Fair Value Of Replacement Options Related To Business Acquisition
AdjustmentsToAdditionalPaidInCapitalFairValueOfReplacementOptionsRelatedToBusinessAcquisition
|
7125000 | USD |
CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
14075000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
514205000 | USD |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13473000 | USD |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
31667000 | USD |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
40518000 | USD |
CY2020 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
24689000 | USD |
CY2019 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
13379000 | USD |
CY2018 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
13929000 | USD |
CY2020 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
9935000 | USD |
CY2019 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
CY2018 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
CY2020 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
119000 | USD |
CY2019 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
978000 | USD |
CY2018 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1279000 | USD |
CY2020 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-2000000 | USD |
CY2019 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | USD |
CY2018 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | USD |
CY2020 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD |
CY2019 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-3196000 | USD |
CY2018 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD |
CY2020 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
2365000 | USD |
CY2019 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
1851000 | USD |
CY2018 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
2875000 | USD |
CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
14075000 | USD |
CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12492000 | USD |
CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8718000 | USD |
CY2020 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-2250000 | USD |
CY2019 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-286000 | USD |
CY2018 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-842000 | USD |
CY2020 | lnth |
Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit
NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit
|
-1334000 | USD |
CY2019 | lnth |
Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit
NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit
|
9725000 | USD |
CY2018 | lnth |
Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit
NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit
|
5762000 | USD |
CY2020 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
2218000 | USD |
CY2019 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
-10635000 | USD |
CY2018 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
2855000 | USD |
CY2020 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
8459000 | USD |
CY2019 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-1994000 | USD |
CY2020 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
2828000 | USD |
CY2019 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-13156000 | USD |
CY2018 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
3219000 | USD |
CY2020 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-1525000 | USD |
CY2019 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-282000 | USD |
CY2018 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-878000 | USD |
CY2020 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
7462000 | USD |
CY2019 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-156000 | USD |
CY2018 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3985000 | USD |
CY2018 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
8690000 | USD |
CY2020 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-1941000 | USD |
CY2019 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
2411000 | USD |
CY2018 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
661000 | USD |
CY2020 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-4224000 | USD |
CY2019 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3233000 | USD |
CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2886000 | USD |
CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-4161000 | USD |
CY2019 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
6077000 | USD |
CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2250000 | USD |
CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
16396000 | USD |
CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
80384000 | USD |
CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
61193000 | USD |
CY2020 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
12474000 | USD |
CY2019 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
22061000 | USD |
CY2018 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
20132000 | USD |
CY2020 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
0 | USD |
CY2019 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
0 | USD |
CY2018 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
1000000 | USD |
CY2020 | us-gaap |
Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
|
10000000 | USD |
CY2019 | us-gaap |
Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
|
0 | USD |
CY2018 | us-gaap |
Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
|
0 | USD |
CY2020 | us-gaap |
Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
|
17562000 | USD |
CY2019 | us-gaap |
Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
|
0 | USD |
CY2018 | us-gaap |
Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
|
0 | USD |
CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-4912000 | USD |
CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-22061000 | USD |
CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-19132000 | USD |
CY2020 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
683000 | USD |
CY2019 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
573000 | USD |
CY2018 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
428000 | USD |
CY2020 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
3777000 | USD |
CY2019 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD |
CY2018 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD |
CY2020 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
0 | USD |
CY2019 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
199461000 | USD |
CY2018 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
0 | USD |
CY2020 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
15491000 | USD |
CY2019 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
275376000 | USD |
CY2018 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
2862000 | USD |
CY2020 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
152000 | USD |
CY2020 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
1224000 | USD |
CY2019 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
2258000 | USD |
CY2018 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
0 | USD |
CY2020 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
77000 | USD |
CY2019 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1173000 | USD |
CY2018 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1152000 | USD |
CY2020 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
2129000 | USD |
CY2019 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
2454000 | USD |
CY2018 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
3386000 | USD |
CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-21861000 | USD |
CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-78881000 | USD |
CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-4668000 | USD |
CY2019 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
76000 | USD |
CY2018 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-282000 | USD |
CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-10225000 | USD |
CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-20482000 | USD |
CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
37111000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
92919000 | USD |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
113401000 | USD |
CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
76290000 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82694000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
92919000 | USD |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
113401000 | USD |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
79612000 | USD |
CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
92919000 | USD |
CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
113401000 | USD |
CY2020Q4 | us-gaap |
Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
|
941000 | USD |
CY2019Q4 | us-gaap |
Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
|
0 | USD |
CY2018Q4 | us-gaap |
Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
|
0 | USD |
CY2020Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
2141000 | USD |
CY2019Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
0 | USD |
CY2018Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
0 | USD |
CY2020 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
340000 | USD |
CY2019 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
274000 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82694000 | USD |
CY2018 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
90000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
92919000 | USD |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
113401000 | USD |
CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
9368000 | USD |
CY2019 | us-gaap |
Interest Paid Net
InterestPaidNet
|
12253000 | USD |
CY2018 | us-gaap |
Interest Paid Net
InterestPaidNet
|
15869000 | USD |
CY2020 | us-gaap |
Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
|
331000 | USD |
CY2019 | us-gaap |
Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
|
2000 | USD |
CY2018 | us-gaap |
Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
|
35000 | USD |
CY2020 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2227000 | USD |
CY2019 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
4175000 | USD |
CY2018 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
7395000 | USD |
CY2020 | lnth |
Consideration Transferred In Acquisition
ConsiderationTransferredInAcquisition
|
419009000 | USD |
CY2019 | lnth |
Consideration Transferred In Acquisition
ConsiderationTransferredInAcquisition
|
0 | USD |
CY2018 | lnth |
Consideration Transferred In Acquisition
ConsiderationTransferredInAcquisition
|
0 | USD |
CY2020 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Description of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”) and for the period from June 19 through December 31, 2020, Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”). See “Progenics Acquisition”.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops, manufactures and commercializes innovative diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart disease, cancer and other diseases. For the Company’s diagnostic agents, they believe that the resulting improved diagnostic information enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs for payers and the entire healthcare system.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics and group practices. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products globally and has operations in the U.S. and Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific and Latin America.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s microbubble ultrasound enhancing agent, DEFINITY, are made in the U.S. and Canada through a DEFINITY direct sales team. In the U.S., the Company’s nuclear imaging products, including TechneLite, Xenon, NEUROLITE and Cardiolite, are primarily distributed through commercial radiopharmacies, the majority of which are controlled by or associated with GE Healthcare, Cardinal, UPPI, Jubilant Radiopharma and PharmaLogic. A small portion of the Company’s nuclear imaging product sales in the U.S. are made through the Company’s direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities. AZEDRA is also sold in the U.S. through an AZEDRA direct sales team. RELISTOR was licensed to Bausch, and the Company collects quarterly royalties based on those sales.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains its own direct sales force in Canada for certain of its products. In Europe, Australia, Asia-Pacific and Latin America, the Company generally relies on third-party distributors to market, sell and distribute its nuclear imaging and ultrasound enhancing agent products, either on a country-by-country basis or on a multi-country regional basis. The Company’s headquarters are located in North Billerica, MA with offices in New York, NY, Somerset, NJ, Montreal, Canada and Lund, Sweden.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progenics Acquisition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the previously announced acquisition of Progenics, by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”).</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer, currently a late stage clinical candidate (“PyL”). Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PyL in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% (which the Company estimates could be approximately $100.0 million) of the total consideration the Company pays in the Progenics Acquisition. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a “Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Replacement Stock Option converted at an exchange ratio determined based on the average of the volume weighted average price per share of common stock of Progenics and Lantheus Holdings prior to the Effective Time, which exchange ratio was 0.31, the same as the Exchange Ratio.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders. Holdings also assumed 34,000 in-the-money Progenics stock options and 6,507,342 out-of-the-money Progenics stock options, each converted into Replacement Stock Options as noted above. In addition, Lantheus assumed Progenics equity plans, which, on an as-converted basis, increased the number of Lantheus shares available for issuance by an aggregate of 4,211,290 shares prior to converting the stock options noted above, subject to certain limitations as to eligibility for issuance.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 8, “Business Combinations”, for further details on the acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of 2020 and through the date of this filing, including the impact of stay-at-home mandates and advisories, and a decline in the volume of procedures and treatments using the Company’s products. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all of its discretionary expenses. In the first quarter of 2020, the Company implemented certain cost reduction initiatives. For most of the second quarter, the Company reduced the Company’s work week from five days to four days and reduced the pay for employees by varying amounts depending on level of seniority.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives and paused new enrollment in the Phase 2 trial of 1095 in metastatic castrate-resistant prostate cancer (“mCRPC”) patients to minimize the risk to subjects and healthcare providers during the pandemic. New enrollment in that study restarted in October 2020. GE Healthcare Limited (“GE Healthcare”), the Company’s development and commercialization partner for flurpiridaz F 18, also delayed enrollment in the second Phase 3 clinical trial of flurpiridaz F 18 because of the pandemic and resumed enrollment in the third quarter of 2020.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The severity of the on-going impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the extent and severity of the impact on the Company's customers and suppliers, all of which are uncertain and cannot be predicted. While the impact of COVID-19 on the Company’s results of operations and cash flows has been, and is expected to continue to be, material, given the continually evolving nature of the pandemic, the Company is currently unable to accurately predict the impact of COVID-19 on its overall 2021 operations and financial results or cash flows for the foreseeable future and whether the impact of COVID-19 could lead to potential future impairments.</span></div> | |
CY2020 | lnth |
Business Combination Consideration Transferred Equity Interests Issued And Issuable Shares
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares
|
26844877 | shares |
CY2020 | lnth |
Business Combination Consideration Transferred Contingent Value Right
BusinessCombinationConsiderationTransferredContingentValueRight
|
86630633 | shares |
CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4211290 | shares |
CY2020 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
ReclassificationsCertain immaterial reclassifications in the prior period consolidated statement of cash flows have been reclassified to conform to the current year period financial statement presentation. | |
CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</span></div> | |
CY2020 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks and Limited Suppliers</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to large national distributors, which in turn, resell the Company’s products.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2022, and renewable by the Company on a year-to-year basis thereafter, and with ANSTO and NTP, running through December 31, 2021. The Company also has a Xenon supply agreement with IRE which runs through June 30, 2022, and which is subject to further extension. The Company currently relies on IRE as the sole supplier of bulk-unprocessed Xenon which the Company processes and finishes for its customers. The Company currently relies on JHS as its sole source manufacturer of DEFINITY, NEUROLITE, Cardiolite and evacuation vials for TechneLite.</span></div> | |
CY2020Q4 | us-gaap |
Other Inventory Capitalized Costs
OtherInventoryCapitalizedCosts
|
0 | USD |
CY2019Q4 | us-gaap |
Other Inventory Capitalized Costs
OtherInventoryCapitalizedCosts
|
0 | USD |
CY2020 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2018 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2019 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2020 | us-gaap |
Advertising Expense
AdvertisingExpense
|
5200000 | USD |
CY2019 | us-gaap |
Advertising Expense
AdvertisingExpense
|
3800000 | USD |
CY2018 | us-gaap |
Advertising Expense
AdvertisingExpense
|
4000000.0 | USD |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2020 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-260000 | USD |
CY2019 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
33000 | USD |
CY2018 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-557000 | USD |
CY2020 | lnth |
Tax Indemnification Agreement Income Expense
TaxIndemnificationAgreementIncomeExpense
|
2218000 | USD |
CY2019 | lnth |
Tax Indemnification Agreement Income Expense
TaxIndemnificationAgreementIncomeExpense
|
-10635000 | USD |
CY2018 | lnth |
Tax Indemnification Agreement Income Expense
TaxIndemnificationAgreementIncomeExpense
|
2855000 | USD |
CY2020 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
238000 | USD |
CY2019 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
686000 | USD |
CY2018 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
167000 | USD |
CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
|
16600000 | USD |
CY2020 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
0 | USD |
CY2019 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
3453000 | USD |
CY2018 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
0 | USD |
CY2020 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
2000 | USD |
CY2019 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
242000 | USD |
CY2018 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
0 | USD |
CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2198000 | USD |
CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-6221000 | USD |
CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2465000 | USD |
CY2020Q4 | us-gaap |
Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
|
600000 | USD |
CY2019Q4 | us-gaap |
Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
|
600000 | USD |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
339410000 | USD |
CY2019 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
347337000 | USD |
CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
343374000 | USD |
CY2020 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
33000 | USD |
CY2019 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
33000 | USD |
CY2020Q4 | us-gaap |
Business Combination Contingent Consideration Asset
BusinessCombinationContingentConsiderationAsset
|
11300000 | USD |
CY2020Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
46757000 | USD |
CY2020Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
15800000 | USD |
CY2020Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
17708000 | USD |
CY2019Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
39530000 | USD |
CY2019Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
0 | USD |
CY2019Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
0 | USD |
CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
|
10100000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
|
1685000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
|
742000 | USD |
CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
|
-1200000 | USD |
CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
3195000 | USD |
CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
800000 | USD |
CY2020Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
11300000 | USD |
CY2020Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
15800000 | USD |
CY2020 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
|
2000000.0 | USD |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-5495000 | USD |
CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
25432000 | USD |
CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
46945000 | USD |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-5984000 | USD |
CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
2603000 | USD |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-11479000 | USD |
CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
28627000 | USD |
CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
49548000 | USD |
CY2020 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
CY2019 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
287000 | USD |
CY2018 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-21000 | USD |
CY2020 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
3158000 | USD |
CY2019 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
-13166000 | USD |
CY2018 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
3424000 | USD |
CY2020 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
170000 | USD |
CY2019 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
114000 | USD |
CY2018 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
-135000 | USD |
CY2020 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
3328000 | USD |
CY2019 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
-12765000 | USD |
CY2018 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
3268000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
6012000 | USD |
CY2020 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-1506000 | USD |
CY2019 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
8712000 | USD |
CY2018 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
7821000 | USD |
CY2020 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-178000 | USD |
CY2019 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
790000 | USD |
CY2018 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
1411000 | USD |
CY2020 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
350000 | USD |
CY2019 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
223000 | USD |
CY2018 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
-3470000 | USD |
CY2020 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-1334000 | USD |
CY2019 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
9725000 | USD |
CY2018 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
5762000 | USD |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1994000 | USD |
CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-3040000 | USD |
CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
9030000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-2411000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
10405000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
1406000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
3210000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
152000 | USD |
CY2020 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Costs
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCosts
|
2723000 | USD |
CY2019 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Costs
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCosts
|
0 | USD |
CY2018 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Costs
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCosts
|
0 | USD |
CY2020 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Recognition Of Deferred Tax Asset Held For Sale
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRecognitionOfDeferredTaxAssetHeldForSale
|
-3000000 | USD |
CY2019 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Recognition Of Deferred Tax Asset Held For Sale
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRecognitionOfDeferredTaxAssetHeldForSale
|
0 | USD |
CY2018 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Recognition Of Deferred Tax Asset Held For Sale
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRecognitionOfDeferredTaxAssetHeldForSale
|
0 | USD |
CY2020 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Section162
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162
|
717000 | USD |
CY2019 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Section162
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162
|
527000 | USD |
CY2018 | lnth |
Effective Income Tax Rate Reconciliation Nondeductible Expense Section162
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162
|
353000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
2818000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
-13156000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
3227000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
|
1065000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
44000 | USD |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1994000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
1457000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
1914000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
2125000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-254000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-238000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
30000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-318000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-22000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-4073000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
-128000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
-2768000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
-1760000 | USD |
CY2020 | lnth |
Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset
EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset
|
590000 | USD |
CY2019 | lnth |
Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset
EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset
|
-2531000 | USD |
CY2018 | lnth |
Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset
EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset
|
731000 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
639000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
635000 | USD |
CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-3040000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
127369000 | USD |
CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
9030000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
|
5867000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
|
5278000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
32030000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
15026000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
404000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
550000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
2553000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
5086000 | USD |
CY2020Q4 | lnth |
Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
|
1325000 | USD |
CY2019Q4 | lnth |
Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
|
1569000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
47095000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
1014000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
56000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
170562000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
74660000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
|
5676000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
|
881000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
91283000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
707000 | USD |
CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
96959000 | USD |
CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
1588000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3456000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
1238000 | USD |
CY2020Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
70147000 | USD |
CY2019Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
71834000 | USD |
CY2020Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
70147000 | USD |
CY2019Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
71834000 | USD |
CY2020Q2 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
92300000 | USD |
CY2019Q4 | lnth |
Unrecognized Tax Benefits Including Interest And Penalties
UnrecognizedTaxBenefitsIncludingInterestAndPenalties
|
27000000.0 | USD |
CY2020Q4 | lnth |
Unrecognized Tax Benefits Including Interest And Penalties
UnrecognizedTaxBenefitsIncludingInterestAndPenalties
|
29900000 | USD |
CY2018Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
9788000 | USD |
CY2019 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
0 | USD |
CY2019 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
4496000 | USD |
CY2019 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
|
0 | USD |
CY2019 | us-gaap |
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
|
0 | USD |
CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
5292000 | USD |
CY2020 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
0 | USD |
CY2020 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | USD |
CY2020 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
|
0 | USD |
CY2020 | us-gaap |
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
|
0 | USD |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
5292000 | USD |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
5300000 | USD |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
|
23500000 | USD |
CY2019Q4 | us-gaap |
Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
|
20700000 | USD |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
|
1000000.0 | USD |
CY2020 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
2800000 | USD |
CY2019 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
-13200000 | USD |
CY2018 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
3200000 | USD |
CY2020Q4 | lnth |
Tax Indemnification Agreement Receivable
TaxIndemnificationAgreementReceivable
|
20800000 | USD |
CY2019Q4 | lnth |
Tax Indemnification Agreement Receivable
TaxIndemnificationAgreementReceivable
|
18900000 | USD |
CY2020 | lnth |
Tax Indemnification Agreement Income Expense
TaxIndemnificationAgreementIncomeExpense
|
2200000 | USD |
CY2019 | lnth |
Tax Indemnification Agreement Income Expense
TaxIndemnificationAgreementIncomeExpense
|
-10600000 | USD |
CY2018 | lnth |
Tax Indemnification Agreement Income Expense
TaxIndemnificationAgreementIncomeExpense
|
2900000 | USD |
CY2020Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
16000000 | USD |
CY2019Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
11417000 | USD |
CY2020Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
11212000 | USD |
CY2019Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
9450000 | USD |
CY2020Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
8532000 | USD |
CY2019Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
8313000 | USD |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
35744000 | USD |
CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
29180000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
196583000 | USD |
CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
208152000 | USD |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
76412000 | USD |
CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
91655000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
120171000 | USD |
CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
116497000 | USD |
CY2020 | us-gaap |
Cost Depreciation Amortization And Depletion
CostDepreciationAmortizationAndDepletion
|
12500000 | USD |
CY2019 | us-gaap |
Cost Depreciation Amortization And Depletion
CostDepreciationAmortizationAndDepletion
|
10300000 | USD |
CY2018 | us-gaap |
Cost Depreciation Amortization And Depletion
CostDepreciationAmortizationAndDepletion
|
10100000 | USD |
CY2020 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
7300000 | USD |
CY2020Q4 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-1800000 | USD |
CY2020Q4 | lnth |
Payment For Contract Termination
PaymentForContractTermination
|
500000 | USD |
CY2020 | us-gaap |
Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
|
350315000 | USD |
CY2019 | us-gaap |
Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
|
382323000 | USD |
CY2020 | us-gaap |
Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
|
-29190000 | USD |
CY2019 | us-gaap |
Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
|
-42032000 | USD |
CY2020Q4 | us-gaap |
Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
|
14020000 | USD |
CY2020Q4 | lnth |
Financial Assurance In Form Of Surety Bond
FinancialAssuranceInFormOfSuretyBond
|
28200000 | USD |
CY2020Q4 | lnth |
Asset Retirement Obligation Liabilities Expected Present Value
AssetRetirementObligationLiabilitiesExpectedPresentValue
|
26900000 | USD |
CY2019Q4 | us-gaap |
Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
|
12883000 | USD |
CY2020 | us-gaap |
Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
|
302000 | USD |
CY2020 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
1439000 | USD |
CY2020Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
148440000 | USD |
CY2020Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
148440000 | USD |
CY2020Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
489945000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
113933000 | USD |
CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
376012000 | USD |
CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
112559000 | USD |
CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
105223000 | USD |
CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
7336000 | USD |
CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
10800000 | USD |
CY2019 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1800000 | USD |
CY2018 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2600000 | USD |
CY2020Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
18300000 | USD |
CY2020 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
2700000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
18628000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
18504000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
17898000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
17824000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
17766000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
136952000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
227572000 | USD |
CY2019Q4 | us-gaap |
Goodwill
Goodwill
|
15714000 | USD |
CY2019Q4 | us-gaap |
Goodwill
Goodwill
|
15714000 | USD |
CY2020 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
42918000 | USD |
CY2020 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
42918000 | USD |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
58632000 | USD |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
58632000 | USD |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
17669000 | USD |
CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
15100000 | USD |
CY2020Q4 | lnth |
Accrued Freight Costs Current
AccruedFreightCostsCurrent
|
5653000 | USD |
CY2019Q4 | lnth |
Accrued Freight Costs Current
AccruedFreightCostsCurrent
|
6260000 | USD |
CY2020Q4 | lnth |
Accrued Rebates Discounts And Chargebacks Current
AccruedRebatesDiscountsAndChargebacksCurrent
|
9350000 | USD |
CY2019Q4 | lnth |
Accrued Rebates Discounts And Chargebacks Current
AccruedRebatesDiscountsAndChargebacksCurrent
|
6985000 | USD |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2925000 | USD |
CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
6917000 | USD |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6129000 | USD |
CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2098000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
41726000 | USD |
CY2019Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
37360000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
20452000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
26296000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
22055000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
148750000 | USD |
CY2020Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
217553000 | USD |
CY2020Q4 | us-gaap |
Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
|
954000 | USD |
CY2020Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
602000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
495000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
218400000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
20701000 | USD |
CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
197699000 | USD |
CY2019Q2 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-3200000 | USD |
CY2019Q4 | lnth |
Capitalized Debt Issuance Cost
CapitalizedDebtIssuanceCost
|
2800000 | USD |
CY2019 | lnth |
Debt Instrument Covenant Compliance Number Of Financial Covenants
DebtInstrumentCovenantComplianceNumberOfFinancialCovenants
|
2 | financial_covenant |
CY2019 | lnth |
Debt Instrument Covenant Leverage Ratio Increase Election Amount Numberof Separate Times
DebtInstrumentCovenantLeverageRatioIncreaseElectionAmountNumberofSeparateTimes
|
2 | time |
CY2016Q4 | lnth |
Royalty Percentage
RoyaltyPercentage
|
0.50 | |
CY2020Q4 | us-gaap |
Interest Rate Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months Net
InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
|
-700000 | USD |
CY2020Q4 | us-gaap |
Aoci Tax Attributable To Parent
AociTaxAttributableToParent
|
500000 | USD |
CY2019Q4 | us-gaap |
Aoci Tax Attributable To Parent
AociTaxAttributableToParent
|
0.0 | USD |
CY2020 | us-gaap |
Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
|
-1503000 | USD |
CY2020 | us-gaap |
Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
|
-415000 | USD |
CY2019 | us-gaap |
Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
|
148000 | USD |
CY2019 | us-gaap |
Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
|
0 | USD |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
6580277 | shares |
CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
14075000 | USD |
CY2019 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12492000 | USD |
CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8718000 | USD |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
272224 | shares |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
17.44 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2027744 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
19.44 | |
CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
8868 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
8.72 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
715881 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
19.47 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.67 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1575219 | shares |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
19.03 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y9M18D | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
229390000 | USD |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1271041 | shares |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
19.72 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P3Y9M18D | |
CY2020Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
228958000 | USD |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.711 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.003 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y6M | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2020 | us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
7100000 | USD |
CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
8868 | shares |
CY2019 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
67558 | shares |
CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
192550 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | USD |
CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
600000 | USD |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2400000 | USD |
CY2020Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
|
1900000 | USD |
CY2020 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M18D | |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1031772 | shares |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
15.20 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
786006 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
15.00 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
610804 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
12.45 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
99108 | shares |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
15.53 | |
CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
935000 | USD |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1107866 | shares |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
16.58 | |
CY2019 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | USD |
CY2018 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | USD |
CY2019Q1 | lnth |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
1100000 | USD |
CY2019Q1 | lnth |
Lease Liability
LeaseLiability
|
1100000 | USD |
CY2020Q4 | lnth |
Number Of Operating Leases
NumberOfOperatingLeases
|
2 | lease |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
18441000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
525000 | USD |
CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
348000 | USD |
CY2020Q4 | lnth |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
18966000 | USD |
CY2019Q4 | lnth |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
1283000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1164000 | USD |
CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
193000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
249000 | USD |
CY2019Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
143000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
17501000 | USD |
CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
812000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
246000 | USD |
CY2019Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
186000 | USD |
CY2020Q4 | lnth |
Lease Liability
LeaseLiability
|
19160000 | USD |
CY2019Q4 | lnth |
Lease Liability
LeaseLiability
|
1334000 | USD |
CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1471000 | USD |
CY2019 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
223000 | USD |
CY2020 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
196000 | USD |
CY2019 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
167000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
0 | USD |
CY2020 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
21000 | USD |
CY2020 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
21000 | USD |
CY2019 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
11000 | USD |
CY2020 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
70000 | USD |
CY2019 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
91000 | USD |
CY2020 | us-gaap |
Lease Cost
LeaseCost
|
1758000 | USD |
CY2019 | us-gaap |
Lease Cost
LeaseCost
|
492000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P9Y8M12D | |
CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y9M18D | |
CY2020Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y4M24D | |
CY2019Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y6M | |
CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.044 | |
CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.051 | |
CY2020Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.053 | |
CY2019Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.054 | |
CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1202000 | USD |
CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
230000 | USD |
CY2019 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
11000 | USD |
CY2020 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
207000 | USD |
CY2019 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
190000 | USD |
CY2020 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
19210000 | USD |
CY2019 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | USD |
CY2020 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
373000 | USD |
CY2019 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
379000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1964000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
231000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2213000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
216000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2255000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
2340000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
0 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
12170000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
78000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2297000 | USD |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54134000 | shares |
CY2019 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
40113000 | shares |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
|
0 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
23239000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
525000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
4574000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
30000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
18665000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
495000 | USD |
CY2018 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
61000 | shares |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13473000 | USD |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
31667000 | USD |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
40518000 | USD |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54134000 | shares |
CY2019 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38988000 | shares |
CY2018 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38233000 | shares |
CY2020 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares |
CY2019 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
75000 | shares |
CY2020 | lnth |
Incremental Common Shares Attributable To Restricted Stock Awards
IncrementalCommonSharesAttributableToRestrictedStockAwards
|
0 | shares |
CY2019 | lnth |
Incremental Common Shares Attributable To Restricted Stock Awards
IncrementalCommonSharesAttributableToRestrictedStockAwards
|
1050000 | shares |
CY2018 | lnth |
Incremental Common Shares Attributable To Restricted Stock Awards
IncrementalCommonSharesAttributableToRestrictedStockAwards
|
1207000 | shares |
CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
343374000 | USD |
CY2020Q4 | us-gaap |
Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
|
700000 | USD |
CY2020Q4 | lnth |
Contingent Payments Under Companys License Agreements
ContingentPaymentsUnderCompanysLicenseAgreements
|
90600000 | USD |
CY2018 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39501000 | shares |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.25 | |
CY2019 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.81 | |
CY2018 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.06 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.25 | |
CY2019 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.79 | |
CY2018 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.03 | |
CY2020 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3175000 | shares |
CY2019 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
50000 | shares |
CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
424000 | shares |
CY2020Q4 | us-gaap |
Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
|
4132000 | USD |
CY2020Q4 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
2066000 | USD |
CY2020Q4 | us-gaap |
Purchase Obligation
PurchaseObligation
|
6198000 | USD |
CY2020 | lnth |
Number Of Patents
NumberOfPatents
|
3 | patent |
CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4198000 | USD |
CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
51661000 | USD |
CY2020 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
800000 | USD |
CY2019 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
2100000 | USD |
CY2018 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
1800000 | USD |
CY2020 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
2 | segment |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
339410000 | USD |
CY2019 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
347337000 | USD |
CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
64488000 | USD |
CY2020 | us-gaap |
Interest Expense
InterestExpense
|
9479000 | USD |
CY2019 | us-gaap |
Interest Expense
InterestExpense
|
13617000 | USD |
CY2020 | us-gaap |
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
|
0 | USD |
CY2019 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
12087000 | USD |
CY2018 | us-gaap |
Interest Expense
InterestExpense
|
17405000 | USD |
CY2019 | us-gaap |
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
|
-3196000 | USD |
CY2018 | us-gaap |
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
|
0 | USD |
CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2198000 | USD |
CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-6221000 | USD |
CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2465000 | USD |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-11479000 | USD |
CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
28627000 | USD |
CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
49548000 | USD |
CY2020 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
23251000 | USD |
CY2018 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
12769000 | USD |
CY2020Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
120171000 | USD |
CY2019Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
116497000 | USD |